Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass. , Feb.